MedPath

Dorzolamide

Generic Name
Dorzolamide
Brand Names
Cosopt, Trusopt
Drug Type
Small Molecule
Chemical Formula
C10H16N2O4S3
CAS Number
120279-96-1
Unique Ingredient Identifier
9JDX055TW1
Background

Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects. First marketed in 1995, dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt or in combination with timolol as Cosopt PF.

Indication

Dorzolamide is indicated for the management of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It can also be used in combination with timolol for the same indication in patients who are insufficiently responsive to ophthalmic beta-blockers.

Its pre-operative use was also investigated to prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy.

Associated Conditions
Increased Intra Ocular Pressure (IOP), Ocular Hypertension
Clinical Trials
Related News

A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Phase 2
Not yet recruiting
Conditions
Primary Open Angle Glaucoma
Ocular Hypertension
Interventions
First Posted Date
2023-12-20
Last Posted Date
2023-12-20
Lead Sponsor
Kukje Pharma
Target Recruit Count
60
Registration Number
NCT06177678
Locations
🇰🇷

Kukje Pharm, Seongnam-si, Korea, Republic of

Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml

Phase 3
Completed
Conditions
Primary Open Angle Glaucoma of Both Eyes
Interventions
Drug: Dorzol 20 mg/ml
First Posted Date
2023-08-02
Last Posted Date
2023-08-02
Lead Sponsor
Jadran Galenski laboratorij d.d.
Target Recruit Count
118
Registration Number
NCT05973305
Locations
🇷🇺

State autonomous healthcare institution 'Republican Clinical Ophthalmological Hospital of the Ministry of Health of the Republic of Tatarstan', Kazan, Russian Federation

Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

Phase 3
Completed
Conditions
Primary Open Angle Glaucoma of Both Eyes
Interventions
Drug: Dorzotimol eye drops, 20 mg/mL + 5 mg/mL
First Posted Date
2023-08-02
Last Posted Date
2023-08-02
Lead Sponsor
Jadran Galenski laboratorij d.d.
Target Recruit Count
110
Registration Number
NCT05973318
Locations
🇷🇺

Republican Clinical Ophthalmological Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation

Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

Phase 4
Completed
Conditions
Ocular Hypertension
Glaucoma, Open-Angle
Interventions
Drug: dorzolamide/timolol
First Posted Date
2023-05-12
Last Posted Date
2024-11-06
Lead Sponsor
Laboratorios Poen
Target Recruit Count
84
Registration Number
NCT05857267
Locations
🇦🇷

Gonella Oftalmólogos, Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aires, Argentina

🇦🇷

Clínica de Ojos Dr. Nano, Olivos, Buenos Aires, Argentina

🇦🇷

Centro Diagnóstico Dr. Gentile, Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aires, Argentina

and more 3 locations

Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema

Phase 2
Conditions
Diabetic Macular Edema
Interventions
Drug: Injections of 1.25 mg of intravitreal bevacizumab with artificial tears
First Posted Date
2021-10-19
Last Posted Date
2021-10-19
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
62
Registration Number
NCT05083689
Locations
🇮🇷

Ophthalmic Research Center, Tehran, Iran, Islamic Republic of

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

Phase 4
Withdrawn
Conditions
Glaucoma
Glaucoma Eye
Glaucoma, Open-Angle
Interventions
Other: Placebo
Dietary Supplement: Lumega-Z
First Posted Date
2020-12-19
Last Posted Date
2022-10-04
Lead Sponsor
University of the Incarnate Word
Registration Number
NCT04676126
Locations
🇺🇸

Ophtalmology Clinic of William E Sponsel, San Antonio, Texas, United States

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma

First Posted Date
2019-05-29
Last Posted Date
2019-05-29
Lead Sponsor
Afyon Kocatepe University Hospital
Target Recruit Count
96
Registration Number
NCT03966560

Pupillary Response After Glaucoma Medication

Not Applicable
Completed
Conditions
Drug Effect (Glaucoma Drugs)
Interventions
First Posted Date
2015-08-13
Last Posted Date
2015-08-13
Lead Sponsor
Glostrup University Hospital, Copenhagen
Target Recruit Count
21
Registration Number
NCT02522039
Locations
🇩🇰

Glostrup University Hospital, Glostrup, Denmark

Stop Retinal Ganglion Cell Dysfunction Study

First Posted Date
2015-03-17
Last Posted Date
2024-10-10
Lead Sponsor
University of Miami
Target Recruit Count
500
Registration Number
NCT02390284
Locations
🇺🇸

Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States

Clinical Evaluation of Patients With X-linked Retinoschisis

Completed
Conditions
XLRS
X-linked Retinoschisis
Interventions
First Posted Date
2015-01-06
Last Posted Date
2017-11-17
Lead Sponsor
Applied Genetic Technologies Corp
Target Recruit Count
66
Registration Number
NCT02331173
Locations
🇺🇸

University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States

🇺🇸

Retina Foundation of the Southwest, Dallas, Texas, United States

🇺🇸

Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy